MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the hematology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
At EHA 2025, early results of the MRD-driven consolidation phase of the trial were presented. In this video, Prof Claudio Cerchione explains why MRD-driven treatment strategies like the one evaluated
Prof Dr Talha Munir and colleagues performed an unanchored, matching-adjusted indirect comparison (MAIC) between continuous zanubrutinib and fixed duration VenO using data from SEQUOIA and CLL14.
At EHA 2025, Dr Dima El-Sharkawi chaired the oral abstract session on indolent non-Hodgkin lymphoma.
During EHA 2025, Prof Dr Krzysztof Giannopoulos chaired a much-anticipated oral abstract session featuring long-term updates of 5 randomized-controlled, clinical trials evaluating new treatment options across different lymphoid malignancies.
During EHA 2025, Prof Timothy Devos presented results of the ongoing, phase II RESTORE trial in which the activin receptor type IIA ligand trap elritercept is being evaluated in the
In this video, Dr Fredrik Schjesvold discusses two studies evaluating a subcutaneous (SC) formulation of the anti-CD38 monoclonal antibody isatuximab in patients with multiple myeloma.(MM)
In this video, Prof Catherine Lambert talks us through the key take home messages from EHA 2025 related to sickle cell disease (SCD).
During EHA 2025, Dr Shira Dinner presented the results of a subgroup analysis of this trial specifically looking at patients below 55 years of age.
